People with #HIV who struggle with adherence achieved viral suppression rates comparable to those in clinical trials when they started long-acting injectable cabotegravir & rilpivirine (Cabenuva), Dr. Monica Gandhi reported at #CROI2023.
https://www.poz.com/article/longacting-injectables-feasible-people-without-viral-suppression

